1. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab. (18th October 2016) Authors: Pierga, J.-Y.; Bidard, F.-C.; Autret, A.; Petit, T.; Andre, F.; Dalenc, F.; Levy, C.; Ferrero, J.-M.; Romieu, G.; Bonneterre, J.; Lerebours, F.; Bachelot, T.; Kerbrat, P.; Campone, M.; Eymard, J.-C.; Mouret-Reynier, M.-A.; Gligorov, J.; Hardy-Bessard, A.-C.; Lortholary, A.; Soulie, P. Journal: Annals of oncology Issue: Volume 28:Number 1(2017) Page Start: 103 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial. (October 2017) Authors: Marino, P.; Sfumato, P.; Joly, F.; Fizazi, K.; Oudard, S.; Culine, S.; Habibian, M.; Boher, J.-M.; Gravis, G. Journal: European journal of cancer Issue: Volume 84(2017) Page Start: 27 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. S236: RANDOMIZED MULTICENTER PHASE III STUDY OF HAPLO VERSUS HLA-MATCHED UNRELATED DONOR (UD) ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION (ALLO HSCT) FOR PATIENTS OLDER THAN 55 YEARS. (23rd June 2022) Authors: Harbi, S.; Boher, J.-M.; Forcade, E.; Chevallier, P.; Peffault De Latour, R.; Malard, F.; Francois, S.; Charbonnier, A.; Hermet, E.; Bulabois, C. E.; Huynh, A.; Berceanu, A.; Cluzeau, T.; Rubio, M. T.; Furst, S.; devillier, R.; Mohty, M.; Blaise, D. Journal: HemaSphere Issue: Volume 6(2022)Supplement 3 Page Start: 137 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗